Table 1.
Overall prevalence of hrHPV (aggregate of 13 types) and of individual hrHPV types detected by INNO-LiPA in the total study population according to baseline cytology.
| HPV Type | HrHPV Prevalence (No. and %) by Cytology Results | Ratio Prevalence HSIL/NILM | |||
|---|---|---|---|---|---|
| NILM (N = 1234) |
ASC-US (N = 131) |
LSIL (N = 113) |
HSIL (N = 114) |
||
| 13 hrHPV * | 187 (15.2%) | 56 (42.8%) | 78 (69.0%) | 98 (86.0%) | 5.7 |
| HPV16 | 32 (2.6%) | 12 (9.2%) | 27 (23.9%) | 56 (49.1%) | 18.9 |
| HPV18 | 12 (1.0%) | 4 (3.1%) | 9 (8.0%) | 10 (8.8%) | 8.8 |
| HPV31 | 54 (4.4%) | 22 (16.8%) | 19(16.8) | 23 (20.2%) | 4.6 |
| HPV33 | 11 (0.9%) | 5 (3.8%) | 9 (8.0%) | 11 (9.7%) | 10.8 |
| HPV35 | 3 (0.2%) | 1 (0.8%) | 0 (0.0%) | 2 (0.9%) | 4.5 |
| HPV39 | 16 (1.3%) | 1 (0.8%) | 5 (4.4%) | 2 (1.8%) | 1.4 |
| HPV45 | 6 (0.5%) | 5 (3.8%) | 4 (3.5%) | 5 (4.4%) | 8.8 |
| HPV51 | 31 (2.5%) | 4 (3.1%) | 9 (8.0%) | 5 (4.4%) | 1.8 |
| HPV52 | 27 (2.2%) | 10 (7.6%) | 11 (9.7%) | 7 (6.1%) | 2.8 |
| HPV56 | 11 (0.9%) | 2 (1.5%) | 7 (6.2%) | 5 (4.4%) | 4.9 |
| HPV58 | 9 (0.7%) | 3 (2.3%) | 7 (6.2%) | 5 (4.4%) | 6.3 |
| HPV59 | 11 (0.9%) | 3 (2.3%) | 4 (3.5%) | 0 (0.0%) | 0 |
| HPV68 | 16 (1.3%) | 5 (3.8%) | 7 (6.2%) | 5 (4.4%) | 3.4 |
NILM, negative for intraepithelial lesion or malignancy; ASC-US, atypical squamous cells of undetermined significance; LSIL, low-grade squamous intraepithelial lesion; HSIL, high-grade squamous intraepithelial. * A positive hrHPV result represents detection of at least one of the 13 hrHPV types included in the HC2: HPV16, HPV18, HPV31, HPV33, HPV35, HPV39, HPV45, HPV51, HPV52, HPV56, HPV58, HPV59 and HPV68. Women infected with multiple HPV types were counted only once.